Liu Yunze, Xu Enwu, Kong Fanyi, Hou Guangjie, He Shiyun, Liang Chaoyang, Liu Yang, Li Chengrun, Shen Leilei, Pei Yanbin, Ren Hong, Guo Juntang
The Chinese PLA Medical School, Beijing 100853, China.
The First Medical Center, Department of Thoracic Surgery, Chinese General Hospital of PLA, Beijing 100853, China.
Eur J Cardiothorac Surg. 2025 Aug 2;67(8). doi: 10.1093/ejcts/ezaf267.
Mediastinal benign teratoma is rare, with surgery being the only effective treatment. Few studies reported the surgical outcomes of resecting mediastinal benign teratomas via the subxiphoid approach by thoracoscopy. This study retrospectively compares the subxiphoid with other surgical approaches, aiming to assess the safety and feasibility of this technique.
We retrospectively analysed the clinical data of 159 patients with pathologically confirmed mediastinal benign teratomas who underwent surgery in 5 hospitals from July 2014 to June 2024. Various parameters of the subxiphoid approach were compared with those of other surgical methods.
The surgical approaches included median sternotomy in 26 cases, lateral thoracotomy in 14 cases, lateral thoracoscopic surgery in 80 cases, subxiphoid thoracoscopic surgery in 26 cases, and robotic surgery in 13 cases. For patients who underwent the subxiphoid approach, the median surgery time was 80 min (70, 90), the median intraoperative blood loss was 20 mL (10, 20), the median postoperative drainage volume was 200 mL (0, 350), and the median time to drain removal was 3 days (0, 3). Complete tumour resection was achieved in all 26 patients (100%). The subxiphoid approach showed advantages in the aforementioned aspects compared to other surgical methods.
The subxiphoid and subcostal arch approach is a safe and feasible surgical technique for benign anterior mediastinal teratoma, with a potentially faster postoperative recovery and less cost. It is a valuable alternative to conventional median sternotomy, lateral thoracotomy, and lateral thoracoscopic surgery in resection of anterior mediastinal teratoma.
纵隔良性畸胎瘤较为罕见,手术是唯一有效的治疗方法。很少有研究报道通过剑突下胸腔镜入路切除纵隔良性畸胎瘤的手术效果。本研究回顾性比较剑突下入路与其他手术入路,旨在评估该技术的安全性和可行性。
我们回顾性分析了2014年7月至2024年6月在5家医院接受手术治疗的159例经病理证实的纵隔良性畸胎瘤患者的临床资料。将剑突下入路的各项参数与其他手术方法的参数进行比较。
手术入路包括正中胸骨切开术26例、侧开胸手术14例、胸腔镜侧胸手术80例、剑突下胸腔镜手术26例和机器人手术13例。接受剑突下入路的患者,中位手术时间为80分钟(70,90),中位术中出血量为20毫升(10,20),中位术后引流量为200毫升(0,350),中位拔管时间为3天(0,3)。26例患者均实现了肿瘤完整切除(100%)。与其他手术方法相比,剑突下入路在上述方面显示出优势。
剑突下和肋弓下入路是治疗前纵隔良性畸胎瘤的一种安全可行的手术技术,术后恢复可能更快且费用更低。在切除前纵隔畸胎瘤方面,它是传统正中胸骨切开术、侧开胸手术和胸腔镜侧胸手术的一种有价值的替代方法。